BOOK
Prostate Cancer, An Issue of Hematology/Oncology Clinics of North America, E-Book
(2013)
Additional Information
Book Details
Abstract
This issue of Hematology/Oncology Clinics is focused on Prostate Cancer and highlights topics such as: Prevention, Early Detection, Biomarkers, Risk stratification, Imaging in Prostate Cancer, Adjuvant hormonal therapy, Management of patient with biochemical relapse, Management of patient with newly metastatic disease, and Bone Health Management.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Prostate Cancer | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| Contents | vii | ||
| Forthcoming Issues | x | ||
| Preface | xi | ||
| Early Detection, PSA Screening, and Management of Overdiagnosis | 1091 | ||
| Key points | 1091 | ||
| Introduction | 1091 | ||
| PSA screening | 1092 | ||
| Randomized controlled trials of PSA screening | 1093 | ||
| PSA screening modifications to improve detection | 1094 | ||
| PSA refinements | 1094 | ||
| PSA Velocity | 1094 | ||
| Free PSA | 1095 | ||
| Complexed PSA | 1095 | ||
| PSA Density | 1096 | ||
| Risk-based screening | 1096 | ||
| Prediction tools | 1096 | ||
| Novel screening tests | 1097 | ||
| PCA3 | 1097 | ||
| Prostate Health Index | 1098 | ||
| TMPRSS2:ERG Gene Fusion | 1098 | ||
| Current screening guidelines | 1098 | ||
| Overdiagnosis in prostate cancer | 1101 | ||
| Impact of overdiagnosis | 1101 | ||
| Watchful waiting and observation | 1102 | ||
| Active surveillance | 1103 | ||
| Summary | 1104 | ||
| References | 1104 | ||
| Surgical Management of Prostate Cancer | 1111 | ||
| Key points | 1111 | ||
| Introduction | 1111 | ||
| Patient selection | 1112 | ||
| Surgical technique | 1113 | ||
| Cavernosal nerve sparing | 1113 | ||
| Pelvic lymph node dissection | 1114 | ||
| Surgical margins | 1115 | ||
| Low-risk prostate cancer | 1116 | ||
| Definition of Low-Risk Prostate Cancer | 1116 | ||
| Outcomes for Low-Risk Disease Following Radical Prostatectomy | 1116 | ||
| High-risk prostate cancer | 1117 | ||
| Definition of High-Risk Prostate Cancer | 1117 | ||
| Outcomes for High-Risk Disease Following Radical Prostatectomy | 1117 | ||
| Neoadjuvant therapy before radical prostatectomy | 1124 | ||
| Is radical prostatectomy the preferred treatment for high-risk prostate cancer? | 1124 | ||
| Alternative Surgical Therapies | 1125 | ||
| Summary | 1125 | ||
| References | 1125 | ||
| Contemporary Issues in Radiotherapy for Clinically Localized Prostate Cancer | 1137 | ||
| Key points | 1137 | ||
| Introduction | 1137 | ||
| Principles of radiation therapy | 1138 | ||
| Patient selection for radiation therapy with curative intent | 1138 | ||
| Risk Stratification | 1138 | ||
| Assessment, Comorbidities, and Contraindications | 1139 | ||
| Defining the radiation target | 1140 | ||
| Prostate and Seminal Vesicles | 1140 | ||
| Whole Pelvic Irradiation | 1141 | ||
| External Beam Radiotherapy\r | 1141 | ||
| IMRT | 1141 | ||
| Image-Guided Radiation Therapy | 1141 | ||
| Dose-Escalated Radiotherapy | 1142 | ||
| Toxicity | 1143 | ||
| Role of Androgen Deprivation Therapy | 1144 | ||
| Brachytherapy | 1144 | ||
| LDR Brachytherapy | 1145 | ||
| Patient selection for brachytherapy | 1145 | ||
| Outcomes | 1145 | ||
| Toxicity | 1146 | ||
| HDR Brachytherapy | 1146 | ||
| Toxicity | 1147 | ||
| Postprostatectomy radiotherapy | 1147 | ||
| PPRT Volume Delineation | 1147 | ||
| Adjuvant Therapy | 1147 | ||
| Salvage Therapy | 1149 | ||
| PPRT Toxicity (Adjuvant and Salvage) | 1149 | ||
| Ongoing Trials | 1150 | ||
| Second malignancy risks from radiotherapy | 1150 | ||
| Future directions in prostate radiotherapy | 1150 | ||
| Anatomic and Molecular Imaging | 1150 | ||
| Hypofractionation | 1151 | ||
| Stereotactic Body Radiotherapy | 1151 | ||
| New Endocrine Therapies | 1151 | ||
| Summary | 1152 | ||
| References | 1152 | ||
| Imaging in Prostate Carcinoma | 1163 | ||
| Key points | 1163 | ||
| Introduction | 1163 | ||
| Imaging modalities commonly used to evaluate prostate cancer | 1164 | ||
| TRUS | 1165 | ||
| MRI | 1165 | ||
| CT | 1166 | ||
| Skeletal Scintigraphy (99mTc-MDP Bone Scan) | 1166 | ||
| PET | 1167 | ||
| Imaging in staging and management of prostate cancer: localized and metastatic disease | 1168 | ||
| Future directions | 1170 | ||
| DCE-MRI | 1172 | ||
| MRSI | 1172 | ||
| DWI | 1173 | ||
| mpMRI | 1173 | ||
| PET | 1173 | ||
| Summary | 1178 | ||
| References | 1178 | ||
| Neoadjuvant and Adjuvant Hormonal and Chemotherapy for Prostate Cancer | 1189 | ||
| Key points | 1189 | ||
| Introduction | 1189 | ||
| Adjuvant hormone therapy following prostatectomy | 1190 | ||
| Adjuvant RT following prostatectomy | 1192 | ||
| Adjuvant androgen deprivation therapy in combination with RT | 1194 | ||
| Adjuvant chemotherapy | 1199 | ||
| Neoadjuvant and adjuvant approaches with new hormonal agents | 1200 | ||
| Future directions | 1201 | ||
| References | 1201 | ||
| Management of Patients with Biochemical Recurrence After Local Therapy for Prostate Cancer | 1205 | ||
| Key points | 1205 | ||
| Introduction | 1205 | ||
| Definition of BCR | 1206 | ||
| BCR After RP | 1206 | ||
| BCR After RT | 1207 | ||
| Natural history of patients with prostate cancer experiencing BCR after surgery or RT | 1207 | ||
| Diagnostic evaluation after PSA recurrence | 1208 | ||
| Salvage radiation for BCR | 1209 | ||
| Salvage prostatectomy postradiation | 1209 | ||
| Hormonal therapy for biochemically recurrent prostate cancer | 1212 | ||
| Continuous Versus Intermittent Administration of ADT | 1213 | ||
| Concerns About Adverse Effects of ADT | 1213 | ||
| Drug development end points for patients with biochemically recurrent prostate cancer | 1214 | ||
| Summary | 1215 | ||
| References | 1215 | ||
| Management of Hormone-Sensitive Metastatic Prostate Cancer | 1221 | ||
| Key points | 1221 | ||
| Introduction | 1221 | ||
| Androgen synthesis and AR | 1222 | ||
| Molecular mechanism underlying prostate cancer progression despite ongoing ADT | 1222 | ||
| AR-Dependent Mechanisms | 1222 | ||
| AR-Independent Mechanisms | 1225 | ||
| Drugs targeting androgen synthesis and AR signaling in metastatic prostate cancer | 1226 | ||
| Targeting Hypothalamic-Pituitary-Testicular Axis | 1226 | ||
| GnRH analogues or agonists | 1226 | ||
| GnRH antagonist | 1226 | ||
| Targeting Androgen Synthesis | 1227 | ||
| Ketoconazole | 1227 | ||
| Abiraterone acetate | 1227 | ||
| TAK-700 (orteronel) | 1227 | ||
| Targeting AR | 1228 | ||
| Antiandrogens | 1228 | ||
| Enzalutamide (MDV3100) | 1228 | ||
| ARN-509 | 1229 | ||
| TOK-001 (galeterone) | 1229 | ||
| EPI-001 | 1229 | ||
| Systemic therapy for HSPC | 1229 | ||
| Castration Versus CAB Therapy | 1229 | ||
| Intermittent ADT Versus Continuous ADT | 1230 | ||
| Combining Chemotherapy with Castration in HSPC | 1230 | ||
| Predicting response to ADT in HSPC | 1231 | ||
| Ongoing studies of ADT in combination with novel agents in HSPC and future directions | 1233 | ||
| References | 1235 | ||
| Management of Patients with Castration-Resistant Disease | 1243 | ||
| Key points | 1243 | ||
| Introduction | 1243 | ||
| Overview of drug classes | 1244 | ||
| Sequencing and response assessment | 1246 | ||
| Targeting of androgen receptor | 1247 | ||
| Abiraterone | 1247 | ||
| Enzalutamide | 1247 | ||
| Novel Hormonal Therapies | 1248 | ||
| TAK-700 | 1248 | ||
| VT 464 | 1248 | ||
| ARN-509 | 1248 | ||
| ODM-201 | 1249 | ||
| TOK-700 | 1249 | ||
| Immunotherapy | 1249 | ||
| Sipuleucel-T | 1249 | ||
| Prostvac | 1250 | ||
| Ipilimumab | 1250 | ||
| Chemotherapy | 1250 | ||
| Docetaxel | 1250 | ||
| Cabazitaxel | 1251 | ||
| Other Chemotherapies | 1252 | ||
| Mitoxantrone | 1252 | ||
| Satraplatin | 1252 | ||
| Novel therapies | 1252 | ||
| 223Radium | 1252 | ||
| Cabozantinib | 1252 | ||
| Custirsen | 1253 | ||
| Tasquinimod | 1253 | ||
| OGX-427 | 1253 | ||
| Other Promising Novel Therapies | 1254 | ||
| Resistance mechanisms | 1254 | ||
| Summary | 1255 | ||
| References | 1255 | ||
| Optimizing Bone Health and Minimizing Skeletal Morbidity in Men with Prostate Cancer | 1261 | ||
| Key points | 1261 | ||
| Introduction | 1261 | ||
| Normal bone physiology | 1262 | ||
| Treatment-related osteoporosis | 1263 | ||
| Bone metastases in prostate cancer | 1264 | ||
| Osteoclast-targeted therapies | 1265 | ||
| Bisphosphonates | 1265 | ||
| Receptor Activator of Nuclear Factor-κβ Ligand Inhibitors | 1267 | ||
| Management of treatment-related osteoporosis | 1267 | ||
| Defining Osteoporosis | 1267 | ||
| Who to Consider for Screening and Treatment? | 1267 | ||
| Pharmacologic Interventions for Treatment-Related Osteoporosis | 1268 | ||
| Bisphosphonates | 1268 | ||
| Receptor activator of nuclear factor-κβ ligand inhibitors | 1268 | ||
| SERMs | 1270 | ||
| Calcium and Vitamin D Supplementation | 1270 | ||
| Lifestyle Modifications | 1270 | ||
| Summary | 1270 | ||
| Use of osteoclast-targeted therapies in metastatic castration-sensitive prostate cancer | 1271 | ||
| Use of osteoclast-targeted therapies in metastatic CRPC | 1271 | ||
| Zoledronic Acid | 1273 | ||
| Denosumab | 1273 | ||
| Summary | 1274 | ||
| Prevention of bone metastases | 1274 | ||
| Zoledronic Acid | 1274 | ||
| Denosumab | 1274 | ||
| Summary | 1275 | ||
| Radiopharmaceuticals | 1275 | ||
| Strontium-89 | 1276 | ||
| Samarium-153 | 1276 | ||
| Radium-223 | 1276 | ||
| Non-bone–targeted therapies documented to decrease SREs | 1277 | ||
| Abiraterone | 1277 | ||
| Enzalutamide | 1277 | ||
| Summary | 1277 | ||
| References | 1278 | ||
| Index | 1285 |